Ph2/3 BMS-986545 + Chemo vs Nivolumab + Chemo in Gastric GEJ or Esophageal
Phase II/III Clinical Trial
ROSETTA Gastric-204: A Blinded Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Participants with Previously Untreated Advanced or Metastatic Gastric Gastroesophageal Junction or Esophageal Adenocarcinoma - CA266-0004
Participating Locations